High-Tech Drugs in Creaky Formulations

Maikel Herbrink; Bastiaan Nuijen; Jan H M Schellens; Jos H Beijnen

doi:10.1007/s11095-017-2185-4

High-Tech Drugs in Creaky Formulations

Maikel Herbrink, Bastiaan Nuijen, Jan H M Schellens, Jos H Beijnen

The Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. [email protected].
The Netherlands Cancer Institute and the Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Recent literature reviews and registration documents covering novel Signal Transduction Inhibitors in the treatment of cancer paint a picture of inefficiency and variability, where formulation improvements could be valuable. In this article, we discuss apparent drug design flaws as we impose the current standard formulation practice.

Original language	English
Pages (from-to)	1751-1753
Number of pages	3
Journal	Pharmaceutical Research
Volume	34
Issue number	9
DOIs	https://doi.org/10.1007/s11095-017-2185-4
Publication status	Published - Sept 2017

Keywords

anticancer drugs
biopharmaceutics
formulation
pharmaceutics

Access to Document

10.1007/s11095-017-2185-4

herbrinkFinal published version, 436 KBLicence: Taverne

Cite this

@article{198a6c0c52604c7a8831de602c83ce74,

title = "High-Tech Drugs in Creaky Formulations",

abstract = "Recent literature reviews and registration documents covering novel Signal Transduction Inhibitors in the treatment of cancer paint a picture of inefficiency and variability, where formulation improvements could be valuable. In this article, we discuss apparent drug design flaws as we impose the current standard formulation practice.",

keywords = "anticancer drugs, biopharmaceutics, formulation, pharmaceutics",

author = "Maikel Herbrink and Bastiaan Nuijen and Schellens, {Jan H M} and Beijnen, {Jos H}",

year = "2017",

month = sep,

doi = "10.1007/s11095-017-2185-4",

language = "English",

volume = "34",

pages = "1751--1753",

journal = "Pharmaceutical Research",

issn = "0724-8741",

publisher = "Springer",

number = "9",

}

TY - JOUR

T1 - High-Tech Drugs in Creaky Formulations

AU - Herbrink, Maikel

AU - Nuijen, Bastiaan

AU - Schellens, Jan H M

AU - Beijnen, Jos H

PY - 2017/9

Y1 - 2017/9

N2 - Recent literature reviews and registration documents covering novel Signal Transduction Inhibitors in the treatment of cancer paint a picture of inefficiency and variability, where formulation improvements could be valuable. In this article, we discuss apparent drug design flaws as we impose the current standard formulation practice.

AB - Recent literature reviews and registration documents covering novel Signal Transduction Inhibitors in the treatment of cancer paint a picture of inefficiency and variability, where formulation improvements could be valuable. In this article, we discuss apparent drug design flaws as we impose the current standard formulation practice.

KW - anticancer drugs

KW - biopharmaceutics

KW - formulation

KW - pharmaceutics

U2 - 10.1007/s11095-017-2185-4

DO - 10.1007/s11095-017-2185-4

M3 - Article

C2 - 28560695

SN - 0724-8741

VL - 34

SP - 1751

EP - 1753

JO - Pharmaceutical Research

JF - Pharmaceutical Research

IS - 9

ER -

High-Tech Drugs in Creaky Formulations

Abstract

Keywords

Access to Document

Fingerprint

Cite this